• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:AU2004233737A1
    申请号:U2004233737
    申请日:2004-04-13
    公开日:2004-11-11
    发明作者:Neema Maheshi Kulkarni；Lori Dee Kumar；Albert Frank Sorg
    申请人:McNeil PPC Inc；
    IPC主号:A61K8-02
    专利说明:
    WO 2004/096192 PCT/IB2004/001270 FAST DISSOLVING ORALLY CONSUMABLE FILMS CONTAINING SUCRALOSE AS A SWEETENER Priority Information 5 This application claims priority to US application number 10/423,398, which is a continuation in part application of US 09/395,104, which claims priority to US provisional application 60/101,798. Field of the Invention 10 The present invention is related generally to fast dissolving orally consumable films for delivering one or more pharmaceutically active agents, and more particularly to fast dissolving orally consumable films containing a sweetener for improving the taste of the film. 15 Background of Related Technologies Personal care products can be formulated in a variety of dosage forms, including tablets, capsules, lozenges or strips of edible thin film compositions. Edible thin film compositions applied to the oral cavity can be designed to deliver therapeutic agents to the oral mucosa. One such example is LISTERINE 20 POCKETPAKSTM brand oral care strip products made by Pfizer Inc. of New York are successful examples of an edible film compositions effective in delivering therapeutic agents particularly antimicrobial agents in the form of a combination of essential oils.
    WO 2004/096192 PCT/IB2004/001270 Conventional rapidly dissolving orally consumable films may have incorporated flavorants and/or sweetening agents to improve the taste of the film and/or its components (e.g., pharmaceutically active agents) contained therein. The flavorants and/or sweetening agents used in such films generally provide limited 5 taste improvement especially for films containing bitter tasting components. Accordingly, there still remains a need in the art to develop consumable thin films containing a sweetener, which at least substantially improves the taste of films and its components. 10 Summary One embodiment of the present invention provides a consumable film adapted to adhere to and dissolve in the oral cavity of a warm-blooded animal including humans, which comprises at least one water soluble polymer, a taste masking effective amount of a sweetener, and a pharmaceutically active agent 15 having a sufficiently unpleasant taste that it is desirably masked by the sweetener. In another embodiment of the present invention, there is provided a consumable film adapted to adhere to and dissolve in the oral cavity of a warm-blooded animal including humans, comprising at least one water soluble polymer, a taste masking effective amount of a sucralose, and a pharmaceutically active agent. 20 The present invention is also directed to a method of preparing a supple, non self-adhering film especially suitable for oral delivery of pharmaceutically active agents where the method comprises preparing a film-forming mixture including at least one water soluble polymer; preparing an aqueous phase comprising a 2 WO 2004/096192 PCT/IB2004/001270 sweetener and a pharmaceutically active agent; combining the aqueous phase and the film forming mixture to form a hydrated polymer gel; casting the hydrated polymer gel on a substrate to form a cast gel; and drying the cast gel to form the consumable film. 5 Detailed Description of the Invention An embodiment of the present invention is directed to a physiologically acceptable film that is well-adapted to dissolve in the oral cavity of a warm-blooded animal including humans afflicted with a disease, symptom or condition, and adhere to the mucosa of the oral cavity. Such films are suited to deliver a pharmaceutically 10 active agent useful for treating the afflicted warm-blooded animal. In one aspect of the present invention, there is provided a consumable film adapted to adhere to and dissolve in the mouth of a warm-blooded animal including humans, comprising at least one water soluble polymer, a taste masking effective 15 amount of a sweetener, and a pharmaceutically active agent having a sufficiently unpleasant taste that it is desirably masked by the sweetener. The consumable film may include one or more of the following ingredients, including, but not limited to, water, antimicrobial agents, additional film forming 20 agents or water soluble polymers, plasticizing agents, flavorings, sulfur precipitating agents, saliva stimulating agents, cooling agents, surfactants, stabilizing agents, emulsifying agents, thickening agents, binding agents, coloring agents, triglycerides, polyethylene oxides, propylene glycols, sweeteners, fragrances, preservatives and the like, as described in co-pending application U.S. Patent Application No. 3 WO 2004/096192 PCT/IB2004/001270 09/395,104, by Leung et al., filed September 14, 1999, which is incorporated herein by reference in its entirety. In one embodiment of the present invention, the consumable film is in the 5 form of a single layer. The term "consumable" as used herein is intended to encompass substances including edible compounds, which upon administration to a consumer, is adequately tolerated without causing undue negative effects. Consumable films are shaped and 10 sized for administration to the oral cavity of a warm-blooded animal including humans. The films are particularly well adapted to rapidly dissolve in the mouth of the warm-blooded animal. The dissolved film adheres to the surface of the mouth, typically the roof of the mouth or the tongue, and can provide a rapid delivery system for pharmaceutically active agents. 15 Unless specified otherwise, the term "% by weight" as used herein with reference to the final product (i.e., the film, as opposed to the formulation used to produce the film), denotes the percent of the total dry weight contributed by the subject ingredient. This theoretical value can differ from the experimental value, 20 because in practice, the film typically retains some of the water and/or other substances such as alcohols (e.g., ethanol) that may be used in preparing the final product. 4 WO 2004/096192 PCT/IB2004/001270 In one embodiment, the consumable film of the present invention includes a pharmaceutically active agent and a sweetener that significantly improves the taste of the pharmaceutically active agent for enhanced product performance and consumer acceptance. By improving the taste of the films containing 5 pharmaceutically active agents in accordance with the present invention, compliance and adherence to treatments involving such films would be significantly enhanced. Suitable sweeteners include natural and artificial sweeteners. Useful sweetening agents include A) water-soluble sweetening agents such 10 as, for example, monosaccharides, disaccharides and polysaccharides, B) water soluble artificial sweetening agents such as, for example, soluble saccharin salts and the like, C) dipeptide based sweetening agents such as L-aspartic acid derived sweetening agents and the like, D) protein based sweeteners such as, for example, thaumatoccous danielli (Thaumatin I and II), and mixtures thereof. Additional 15 suitable sweeteners include sucralose, aspartame, acesulfame potassium, neotame, saccharin, xylitol and mixtures thereof. The sweetener is employed in an effective amount, which will vary depending in part on the specific sweetener chosen. A "taste masking effective amount" is 20 meant to be an amount of the sweetener that is sufficient to at least reduce, mask or eliminate the unpleasant taste (e.g., bitter) of the pharmaceutically active agent contained in the film of the present invention. In addition to the particular sweetener, the taste masking effective amount may vary with the type and/or the degree of the taste being masked and the particular carrier and ingredients contained in the film. 5 WO 2004/096192 PCT/IB2004/001270 In one embodiment, the sweetener may be present in the dry film of the present invention in taste masking effective amounts ranging from about 0.1% to 10% by weight, preferably 1% to 6% by weight, and more preferably from about 2% to 4% by weight of the film. 5 One embodiment includes sucralose as a sweetener. Sucralose is a chlorinated sucrose derivative having an intensely sweet taste. Sucralose has been discovered to effectively mask or nullify the unpleasant taste attributes of many food additives and pharmaceutically active agents especially those that are bitter tasting. 10 By incorporating sucralose into the films of the present invention, enhanced sweetness and desirable masking of any unpleasant taste supplanted by food additives and pharmaceutically active agents (e.g., dextromethorphan hydrobromide, famotidine) that may be contained therein, will be beneficially realized. 15 The water soluble polymers of the present invention possess film forming properties useful producing the films of the present invention. The water soluble polymer used in the films of the present invention can be selected from the group consisting of pullulan, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl 20 alcohol, sodium alginate, polyethylene glycol, tragacanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methylmethacrylate copolymers, carboxyvinyl polymers, amylose, high amylose starch, hydroxypropylated high amylose starch, dextrin, pectin, chitin, chitosan, levan, elsinan, collagen, gelatin, zein, gluten, soy protein isolate, whey protein isolate, casein and mixtures thereof. In one 6 WO 2004/096192 PCT/IB2004/001270 embodiment of the present invention the water soluble polymer is pullulan which may be present in amounts ranging from about 0.01% to 99% by weight, in another embodiment from about 10% to 80% by weight, in another embodiment from about 20% to 70% by weight of the film and in yet another embodiment from about 30% to 5 50% by weight of the film. The term "pharmaceutically active agents" as used herein is intended to encompass agents other than food additives, which promote a structural and/or functional change in and/or on bodies to which they have been administered. These 10 agents are not particularly limited, however, they should be physiologically acceptable and compatible with the film. Suitable pharmaceutically active agents that may be unpleasant to the taste, include, but are not limited to, (a) antimicrobial agents such as triclosan, cetyl pyridium chloride, domiphen 15 bromide, quaternary ammonium salts, zinc compounds, sanguinarine, fluorides, alexidine, octonidine, EDTA, and the like; (b) non-steroidal anti-inflammatory drugs such as aspirin, acetaminophen, ibuprofen, ketoprofen, diflunisal, fenoprofen calcium, flurbiprofen sodium, naproxen, tolmetin sodium, indomethacin, celecoxib, rofecoxib and the like; 20 (c) antitussives such as benzonatate, caramiphen edisylate, menthol, dextromethorphan hydrobromide, chlophedianol hydrochloride and the like; (d) decongestants such as pseudoephedrine hydrochloride, phenylepherine, phenylpropanolamine, pseudoephedrine sulfate and the like; 7 WO 2004/096192 PCT/IB2004/001270 (e) antihistamines such as brompheniramine maleate, chlorpheniramine maleate, carbinoxamine maleate, clemastine fumarate, dexchlorpheniramine maleate, diphenylhydramine hydrochloride, azatadine maleate, diphenhydramine citrate, diphenylpyraline hydrochloride, doxylamine succinate, promethazine 5 hydrochloride, pyrilamine maleate, tripelennamine citrate, triprolidine hydrochloride, acrivastine, brompheniramine, dexbropheniramine, fexofenadine, loratadine, cetirizine, and the like; (f) expectorants such as guaifenesin, ipecac, potassium iodide, terpin hydrate and the like; 10 (g) antidiarrheals such as loperamide and the like; (h) histamine II receptor antagonists such as famotidine, ranitidine and the like; (i) proton pump inhibitors such as omerprazole, lansoprazole and the like; (j) general nonselective CNS depressants such as aliphatic alcohols, 15 barbiturates and the like; (k) general nonselective CNS stimulants such as caffeine, nicotine, strychnine, picrotoxin, pentylenetetrazol and the like; (I) drugs that selectively modify CNS function such as phenyhydantoin, phenobarbital, primidone, carbamazepine, ethosuximide, methsuximide, 20 phensuximide, trimethadione, diazepam, benzodiazepines, phenacemide, pheneturide, acetazolamide, sulthiame bromide, gabapentin, phenytoin and the like; (m) antiparkinsonism drugs such as levodopa, amantadine and the like; 8 WO 2004/096192 PCT/IB2004/001270 (n) narcotic-analgesics such as morphine, heroin, hydromorphone, metopon, oxymorphone, levorphanol, codeine, hydrocodone, oxycodone, nalorphine, naloxone, naltrexone and the like; (o) analgesic-antipyretics such salicylates, phenylbutazone, indomethacin, 5 phenacetin and the like; and (p) psychopharmacological drugs such as chlorpromazine, methotrimeprazine, haloperidol, clozapine, reserpine, imipramine, tranylcypromine, phenelzine, lithium and the like. 10 The pharmaceutically active agent is employed in an effective amount, which will vary depending, in part on the pharmaceutically active agent chosen. An "effective amount" is meant to be an amount of the pharmaceutically active agent that sufficient to at least reduce or relieve the condition, symptom or disease being treated, but low enough to avoid any adverse side effects. In addition to the 15 particular active agent, the effective amount of the pharmaceutically active agent may vary with the type and/or severity of the disease, symptom or condition, the age and physical condition of the patient being treated, the duration of treatment, the nature of concurrent therapy, the specific form (i.e., salt) of the pharmaceutically active agent employed, and the particular carrier from which the pharmaceutically 20 active agent is applied. The amount of the pharmaceutically active agent in the formulation may be adjusted to deliver a predetermined dose of the pharmaceutically active agent over a predetermined period of time, which may typically vary from 4 to 24 hours. For 9 WO 2004/096192 PCT/IB2004/001270 example, in one embodiment of the present invention, the film may be administered at one dose every 12 hours to deliver a pharmaceutically effective amount of the pharmaceutically active agent such as dextromethorphan, for example, over a period of 12 hours to a patient in need of such administration. A typical adult dose of a 5 pharmaceutically active agent of the present film may contain from about 0.1 to 130 mg, preferably from about 0.1 to 65 mg of the pharmaceutically active agent (e.g., dextromethorphan hydrobromide). Examples of doses for specific pharmaceutically active agents that can be o10 delivered per one strip of rapidly dissolving oral film are reviewed in Table A. 10 WO 2004/096192 PCT/IB2004/001270 Table A Pharmaceutically Active Agent Dose Chlorpheniramine Maleate 4-12 mg Brompheniramine Maleate 4 mg Dexchlorpheniramine 2 mg Dexbropheniramine 2 mg Triprolidine Hydrochloride 2.5 mg Cetirizine 5-10 mg Acrivastine 8 mg Azatadine Maleate 1 mg Loratadine 5-10 mg Phenylephrine Hydrochloride 5-10 mg Dextromethorphan Hydrobromide 10-30 mg Sildenafil 25-100 mg Ketoprofen 12.5-25 mg Sumatriptan Succinate 35-70 mg Zolmitriptan 2.5 mg Loperamide 2 mg Famotidine 5-10 mg Nicotine 1-15 mg Diphenhydramine Hydrochloride 12.5-25 mg Pseudoephedrine Hydrochloride 15-60 mg Atorvastatin 5-80 mg Valdecoxib 5-20 mg Amlodipine besylate 2.5-10 mg Rofecoxib 5-25 mg Setraline hydrochloride 10-100 mg Ziprasidone 20-80 mg Eletriptan 10-40 mg Nitroglycerin 0.3-0.6 mg Except as otherwise noted, the amount of active agent in the film according to 5 the present invention is designated as % by weight after the film formulation has been dried and formed into the film. Generally, the amount of the active agent used in the film may be from about 0.01% to about 80% by weight, preferably from about 2.5% to about 40% by weight, and more preferably from about 5% to about 30% by weight. 11 WO 2004/096192 PCT/IB2004/001270 The film compositions of the present invention may also be used to supply nutritionally acceptable components such as vitamins, minerals, trace elements, and fibers (preferably soluble fibers). 5 Examples of vitamins suitable for the incorporation in the composition of the invention include Vitamin A, Vitamin D, Vitamin E, Vitamin K, Vitamin C, folic acid, thiamin, riboflavin, Vitamin B (6), Vitamin B (12), niacin, biotin and panthotenic acid in pharmaceutical or nutritionally acceptable form. Examples of mineral elements 10 and trace elements suitable for the incorporation in the composition of the invention include calcium, sodium, potassium, phosphorous, magnesium, manganese, copper, zinc, iron, selenium, chromium and molybdenum in pharmaceutical or nutritionally acceptable form. 15 The term soluble fiber as used herein refers to fibers which are able to substantially undergo fermentation in the colon to produce short chain fatty acids. Examples of suitable soluble fibers include, carubin, pectin, tragacanth, cereal beta glucan and the like. They may be hydrolysed or not. 20 In another embodiment of the present invention, the consumable film may further include antimicrobial agents including, but not limited to, essential oils as is described in co-pending U.S. Patent Application No. 09/395,104, by Leung et al., filed September 14, 1999, which is incorporated herein by reference in its entirety. Such essential oils may be selected from, for example, carvacrol, thymol, eucalyptol, 12 WO 2004/096192 PCT/IB2004/001270 menthol, methyl salicylate, eugenol, gerianol, verbenone and the like and combinations thereof. One of the preferred combinations of essential oils is utilized in LISTERINE® brand mouthwash and oral care strips, which are, perhaps, the most well known examples of antiseptic oral compositions that has proven effective in 5 killing microorganisms in the oral cavity that are responsible for plaque, gingivitis and bad breath. LISTERINE® brand mouthwash and oral care strips achieve their antimicrobial effect through a combination of essential oils. These essential oils include precisely balanced amounts of thymol, methyl salicylate, menthol and eucalyptol (hereinafter "the preferred essential oils") effective in killing the 10 undesirable microorganisms. The amounts of the preferred essential oils used in the film compositions can vary as long as they are in amounts sufficient to provide antimicrobial efficacy. Generally, the amount of essential oils is up to about 30% and preferably from about 15 0.05% to about 18% by weight of the film. In one preferred embodiment, the amount of thymol, methyl salicylate and eucalyptol is each from about 0.01% to about 4% by weight, preferably from about 0.05% to about 3.0% by weight and more preferably from about 0.07% to about 2.0% by weight of the film. Menthol may be present in an amount of from about 0.01% to about 15% by weight of the composition, preferably 20 from about 2.0% to about 9.0% by weight and more preferably from about 3% to about 9% by weight of the film. A desirable and useful amount of essential oils including the preferred essential oils can be readily determined by those skilled in the art and may exceed the preferred amounts as long as the total essential oil content does not create processing problems such as sticking. In certain embodiments, the 13 WO 2004/096192 PCT/IB2004/001270 essential oils are combined in amounts synergistically effective to kill plaque producing germs that cause dental plaque, gingivitis and bad breath. For embodiments incorporating essential oils, humectants are avoided due to 5 the relatively high content of oil in the consumable, so as to avoid producing an overly moist, self-adhering film. In an embodiment, the consumable film includes a plasticizing agent other than glycerin, which is also a humectant, and with a sweetener other than sorbitol, which is a mild humectant. 10 Saliva stimulating agents may also be added to the consumable films of the present invention. Useful saliva stimulating agents are disclosed in U.S. Pat. No. 4,820,506, which is incorporated herein by reference in its entirety. The consumable films of the present invention may also include a 15 preservative. The preservative is added in amounts up to about 5%, preferably from about 0.01% to 1% by weight of the film. Preferred preservatives include sodium benzoate, methyl parabens, propyl parabens and potassium sorbate. Other suitable preservatives include, but are not limited to, salts of edetate, (also known as salts of ethylenediaminetetraacetic acid, or EDTA, such a disodium EDTA). 20 Another embodiment of the present invention is directed to methods of preparing consumable films of the present invention. Generally, at least one --antitussive-agent-and-a mucosa-coating effective-amount of a mucosa-coating agent 14 WO 2004/096192 PCT/IB2004/001270 are dissolved in water to form an aqueous phase. The aqueous phase may further include sweeteners, dyes, and the like. A film forming mixture comprising at least one water soluble polymer (e.g., pullulan) is prepared. The aqueous phase and the film forming mixture are combined and thoroughly mixed to form a hydrated polymer 5 gel. Optionally, an organic phase comprising organic ingredients such as essential oils and other oils (e.g. glycerine, olive oil) flavorants, surfactants (e.g., Polysorbate 80, Atmos 300, Atsurf 596K); and the like, may be combined with the aqueous phase, the film forming mixture or the hydrated polymer gel. The resulting hydrated polymer gel is cast on a suitable substrate to form a cast gel. The cast gel is then 10 dried to form the consumable film. In another embodiment there is provided a method of preparing the consumable film, it may be desirable to first form the film forming mixture by first hydrating the water soluble polymer with water. The aqueous phase is then 15 prepared by dissolving the other water soluble ingredients such as the antitussive agent, the mucosa-coating agent (e.g., pectin), sweeteners, dyes, and the like in water. Separately, the organic ingredients such as essential oils and other oils (e.g. glycerine, olive oil) flavorants, surfactants (e.g., Polysorbate 80, Atmos 300, Atsurf 596K); and the like are mixed together. The final formulation is then produced by 20 mixing the film forming polymer phase with the aqueous phase, then adding the organic phase. The combined mixture is formed into an emulsion or a hydrated polymer gel. 15 WO 2004/096192 PCT/IB2004/001270 The resulting hydrated polymer gel is then cast on a suitable substrate and dried to form a film. The consumable film is preferably air-dried and dried under warm air and cut to a desired dimension, packaged and stored. The packaged film may contain moisture in amounts of from about 0.1% to about 10% by weight, and 5 more preferably from about 4% to about 7% by weight. The film forming mixture may further include stabilizing agents such as xanthan gum, locust bean gum, carrageenan, and the like, and combinations thereof. These ingredients are mixed and then hydrated in warm water, preferably deionized 10 water until a gel is formed which may take from about 30 to about 48 hours. The water is preferably heated to a temperature of from about 20LC to about 403C to promote hydration. The amount of water is typically from about 40% to about 80% by weight of the gel. The resulting hydrated gel is then chilled to a temperature of from about 20-C to about 30-C for about 1 hour to about 48 hours. 15 The aqueous phase may, in addition to the antitussive agent and the mucosa coating effective amount of the mucosa-coating agent such as pectin, include additives such as coloring agents, copper gluconate and sweetener. Typically the aqueous phase contains from about 5% to about 80% by weight based on the total 20 weight of the final gel mixture. If sodium saccharin as a selected sweetener and copper gluconate as a selected sulfur precipitating agent are used in the formulation, it is preferable to dissolve them separately in solution to avoid precipitation. 16 WO 2004/096192 PCT/IB2004/001270 In another embodiment of the present invention, the water soluble polymer is in the form of a powder which is added to the aqueous phase to form a hydrated polymer gel. The resulting hydrated polymer gel is thoroughly stirred at about room 5 temperature for about 30 minutes to about 48 hours, and then deaerated to remove at least substantially all the air bubbles. The uniform mixture is cast on a suitable substrate, and thereafter dried to form the desired film. For consumable films containing essential oils, the essential oils are further 10 added to the organic phase and the mixing the organic phase with the hydrated polymer gel. In particular, the essential oils such as menthol and thymol can be mixed optionally in combination with oils to form an oil mixture. Other essentials oils such as methyl salicylate and eucalyptol, and surfactants can then be added to the oil mixture. The oil mixture is then added to the hydrated polymer gel and mixed 15 until a uniform gel is formed. The uniform gel is then cast on a suitable substrate, and thereafter dried to form the consumable film. In one embodiment for preparing the consumable film, the water soluble polymer may be hydrated without heating the water to reduce energy costs in the 20 manufacturing process. Moreover, since heating may result in undesirable losses of volatile ingredients to evaporation, it would be preferable to avoid heating during the hydration process. For essential oil-containing films, the heat may also affect the germ killing activity of the composition due to the loss of essential oils. 17 WO 2004/096192 PCT/IB2004/001270 While not wishing to be bound by any theory, it is believed that the film forming ingredients such as the water soluble polymers can be hydrated and mixed without heating due to an ionic effect known as the Donnan equilibrium. Hydrating the water soluble polymers in the presence of electrolytes in solution effectively 5 lowers the viscosity of the polymer gel being formed, thus increasing the efficiency of the hydrating process. The water-soluble ingredients of the formulation provide the electrolytes, which are dissolved in the hydration solution prior to addition to the water-soluble polymers. High shear mixing also accelerates hydration, which delumps the powders, providing greater surface area for water contact. In addition, 10 local heating effects, generated in the shear regions, provide energy for hydration without substantially raising the temperature of the mass. EXAMPLE 1 15 The ingredients listed in Table 1 were combined to provide a consumable film of the present invention in accordance with the following procedure: A) Dextromethorphan HBr was mixed and dissolved in 90% water at 75-C to yield an aqueous phase. Amberlite IRP69 was added to the aqueous phase and stirred for about 4 to 5 hours at about 7 0-C to 8 0LC. The aqueous phase was 20 allowed to cool to about 50-C and q.s. with water to replace loss due to evaporation. Potassium sorbate and dye were then added to the aqueous phase and mixed thoroughly. 18 WO 2004/096192 PCT/IB2004/001270 B) The film-forming ingredients, xanthan gum, locust bean gum, carrageenan and pullulan were mixed together in a separate container to form a film forming mixture. C) The film forming mixture was slowly added to the aqueous phase of A), 5 followed by overnight mixing at a slow rate to provide a hydrated polymer gel. D) The flavorants, glycerine, menthol, polysorbate 80 and Atmos 300 were combined and mixed to dissolve in a separate container to yield an organic phase. E) Mannitol and sucralose were mixed together in the remaining 10% water in a separate container. Succulence was then added to the resulting mixture and 10 dissolved. F) The mixtures of steps D) and E) were added to the hydrated polymer gel and mixed uniformly to yield a final polymer gel mixture. The final polymer gel mixture was poured on a mold and cast to form a film of a desired thickness at room temperature. The film was dried under warm air and cut to a desired dimension 15 (dictated by e.g., dosage and mouthfeel). 19 WO 2004/096192 PCT/IB2004/001270 Table 1 %w/w*%w/w Material mg/dose* %w/w* %ww g/batch Dry Film Actual Batch Dextromethorphan HBr 15.0000 22.7322 7.7289 38.6447 Amberlite IRP69 16.0000 24.2477 8.2442 41.2211 Xanthan Gum 0.0769 0.1165 0.0396 0.1981 Locust Bean Gum 0.0901 0.1365 0.0464 0.2321 Carrageenan 0.3861 0.5851 0.1989 0.9947 Pullulan 20.5919 31.2066 10.6102 53.0512 Potassium sorbate 0.0772 0.1170 0.0398 0.1989 Purified water - - 66.0000 330.0000 Menthol 2.5740 3.9008 1.3263 6.6314 Peppermint Flavor 0.2579 0.3908 0.1329 0.6644 Cherry Flavor (Givudan) 0.2579 0.3908 0.1329 0.6644 Sour Cherry (I FF) 2.2350 3.3871 1.1516 5.7581 Warm Sensation (Mane) 0.5518 0.8362 0.2843 1.4216 Artificial Masking Agent 0.4139 0.6273 0.2133 1.0663 Flavor (Robertet) 0.4139 0.6273 0.2133 1.0663 Succulence (IFF) 0.2579 0.3908 0.1329 0.6644 FD&C Red #40 0.0098 0.0149 0.0050 0.0252 Polysorbate 80 NF 0.4504 0.6826 0.2321 1.1604 Atmos 300 0.4504 0.6826 0.2321 1.1604 Glycerine 1.9305 2.9256 0.9947 4.9736 Mannitol USP 2.5740 3.9008 1.3263 6.6314 Sucralose 1.8000 2.7279 0.9275 4.6374 Total 65.9857 100.0000 100.0000 500.0000 *Assuming that all water is evaporated 20 WO 2004/096192 PCT/IB2004/001270 EXAMPLE 2 The ingredients listed in Table 2 were combined to provide a consumable film of the present invention in accordance with the following procedure: 5 A) Dextromethorphan HBr was mixed and dissolved in 90% water at 7 5C to yield an aqueous phase. Amberlite IRP64 was added to the aqueous phase and stirred for about 4 to 5 hours at about 70LC to 802C. Pectin was mixed with glycerine and the mixture was added very slowly to the aqueous phase and then mixed thoroughly at a high rate. The aqueous phase was allowed to cool to about 50°C 10 and q.s. with water to replace loss due to evaporation. Potassium sorbate and dye were then added to the aqueous phase and mixed thoroughly. B) The film-forming ingredients, xanthan gum, locust bean gum, carrageenan and pullulan were mixed together in a separate container to form a film forming mixture. 15 C) The film forming mixture was slowly added to the aqueous phase of A), followed by overnight mixing at a slow rate to provide a hydrated polymer gel. D) The flavorants and menthol were combined and mixed to dissolve in a separate container to yield an organic phase. E) Mannitol and sucralose were mixed together in the remaining 10% water 20 in a separate container. Succulence was then added to the resulting mixture and dissolved. F) The mixtures of steps D) and E) were added to the hydrated polymer gel and mixed uniformly to yield a final polymer gel mixture. The final polymer gel mixture was poured on a mold and cast to form a film of a desired thickness at room 21 WO 2004/096192 PCT/IB2004/001270 temperature. The film was dried under warm air and cut to a desired dimension (dictated by e.g., dosage and mouthfeel). Table 2 m %w/w* %w/w Material mg/dose* %WW WW g/batch Material Dry Film Actual Batch g/batch Dextromethorphan HBr 15.0000 22.9235 7.8353 39.1765 Amberlite IRP64 16.0000 24.4518 8.3576 41.7882 Pectin USP 0.3500 0.5349 0.1828 0.9141 Xanthan Gum 0.0769 0.1175 0.0402 0.2008 Locust Bean Gum 0.0901 0.1377 0.0471 0.2353 Carrageenan 0.3861 0.5901 0.2017 1.0084 Pullulan 20.5919 31.4693 10.7562 53.7812 Potassium sorbate 0.0772 0.1180 0.0403 0.2016 Purified water - - 65.8199 329.0995 Menthol 2.5740 3.9337 1.3445 6.7227 Peppermint Flavor 0.2579 0.3941 0.1347 0.6736 Cherry Flavor (Givudan) 0.2579 0.3941 0.1347 0.6736 Sour Cherry (IFF) 2.2350 3.4156 1.1675 5.8373 Warm Sensation (Mane) 0.5518 0.8433 0.2882 1.4412 Artificial Masking Agent 0.4139 0.6325 0.2162 1.0810 Flavor (Robertet) Succulence (IFF) 0.2579 0.3941 0.1347 0.6736 FD&C Red #40 0.0098 0.0150 0.0051 0.0256 Glycerine 1.9305 2.9503 1.0084 5.0420 Mannitol USP 2.5740 3.9337 1.3445 6.7227 Sucralose 1.8000 2.7508 0.9402 4.7012 Total 65.4349 100.0000 100.0000 500.0000 *Assuming that all water is evaporated 5 22 WO 2004/096192 PCT/IB2004/001270 EXAMPLE 3 The ingredients listed in Table 3 were combined to provide a consumable film of the present invention in accordance with the following procedure: 5 A) Dextromethorphan HBr was mixed and dissolved in 90% water at 75PC to yield an aqueous phase. Amberlite IRP69 was added to the aqueous phase and stirred for about 4 to 5 hours at about 70°C to 802C. Pectin was added to the aqueous phase very slowly and mixed at high speed. The aqueous phase was allowed to cool to about 50°C and q.s. with water to replace loss due to evaporation. 10 Potassium sorbate, sweeteners and dye were then added to the aqueous phase and mixed thoroughly. B) The film-forming ingredients, xanthan gum, locust bean gum, carrageenan and pullulan were mixed together in a separate container to form a film forming mixture. 15 C) The film forming mixture was slowly added to the aqueous phase of A), followed by overnight mixing at a slow rate to provide a hydrated polymer gel. D) The flavorants, glycerine, menthol, and surfactants were combined and mixed to dissolve in a separate container to yield an organic phase. E) Mannitol was mixed together in the remaining 10% water in a separate 20 container. Succulence was then added to the resulting mixture and dissolved. F) The mixtures of steps D) and E) were added to the hydrated polymer gel and mixed uniformly to yield a final polymer gel mixture. The final polymer gel mixture was poured on a mold and cast to form a film of a desired thickness at room 23 WO 2004/096192 PCT/IB2004/001270 temperature. The film was dried under warm air and cut to a desired dimension (dictated by e.g., dosage and mouthfeel). Table 3 , %w/w* %w/w Material mg/dose* D Fu g/batch Dry Film Actual Batch Dextromethorphan HBr 15.0000 22.6123 7.7289 38.6445 Amberlite IRP69 16.0000 24.1197 8.2442 41.2208 Pectin USP 0.3500 0.5276 0.1803 0.9017 Xanthan Gum 0.0769 0.1159 0.0396 0.1981 Locust Bean Gum 0.0901 0.1358 0.0464 0.2321 Carrageenan 0.3861 0.5820 0.1989 0.9947 Pullulan 20.5919 31.0420 10.6102 53.0509 Potassium sorbate 0.0772 0.1164 0.0398 0.1989 Purified water - 65.8199 329.0995 Menthol 2.5740 3.8803 1.3263 6.6314 Peppermint Flavor 0.2579 0.3888 0.1329 0.6644 Cherry Flavor (Givudan) 0.2579 0.3888 0.1329 0.6644 Cherry Flavor Blend (IFF) 2.2350 3.3692 1.1516 5.7580 Warm Sensation (Mane) 0.5518 0.8318 0.2843 1.4216 Artificial Masking Agent 0.4139 0.6239 0.2133 1.0663 Flavor (Robertet) Succulence (IFF) 0.2579 0.3888 0.1329 0.6644 FD&C Red #40 0.0098 0.0148 0.0050 0.0252 Polysorbate 80 NF 0.4504 0.6790 0.2321 1.1604 Atmos 300 0.4504 0.6790 0.2321 1.1604 Glycerine 1.9305 2.9102 0.9947 4.9735 Mannitol USP 2.5740 3.8803 1.3263 6.6314 Sucralose 1.8000 2.7135 0.9275 4.6373 Total 66.3357 100.0000 100.0000 500.0000 *Assuming that all water is evaporated 5 24 WO 2004/096192 PCT/IB2004/001270 EXAMPLE 4 The ingredients listed in Table 4 were combined to provide a consumable film of the present invention in accordance with the following procedure: 5 A) Dextromethorphan HBr was mixed and dissolved in 90% water at 7 5-C to yield an aqueous phase. Amberlite IRP64 was added to the aqueous phase and stirred for about 4 to 5 hours at about 702C to 80-C. Pectin was added to the aqueous phase very slowly and mixed at a high mixing rate. The aqueous phase was allowed to cool to about 502C and q.s. with water to replace loss due to 10 evaporation. Potassium sorbate and dye were then added to the aqueous phase and mixed thoroughly. B) The film-forming ingredients, xanthan gum, locust bean gum, carrageenan and pullulan were mixed together in a separate container to form a film forming mixture. 15 C) The film forming mixture was slowly added to the aqueous phase of A), followed by overnight mixing at a low mixing rate to provide a hydrated polymer gel. D) The flavorants, glycerine, menthol, and surfactants were combined and mixed to dissolve in a separate container to yield an organic phase. E) Mannitol and sucralose were mixed together in the remaining 10% water 20 in a separate container. Succulence was then added to the resulting mixture and dissolved. F) The mixtures of steps D) and E) were added to the hydrated polymer gel and mixed uniformly to yield a final polymer gel mixture. The final polymer gel mixture was poured on a mold and cast to form a film of a desired thickness at room 25 WO 2004/096192 PCT/IB2004/001270 temperature. The film was dried under warm air and cut to a desired dimension (dictated by e.g., dosage and mouthfeel). Table 4 Material mg/dose* %w/w* %w/w g/batch Dry Film Actual Batch Dextromethorphan HBr 15.0000 22.6123 7.7289 38.6445 Amberlite IRP64 16.0000 24.1197 8.2442 41.2208 Pectin USP 0.3500 0.5276 0.1803 0.9017 Xanthan Gum 0.0769 0.1159 0.0396 0.1981 Locust Bean Gum 0.0901 0.1358 0.0464 0.2321 Carrageenan 0.3861 0.5820 0.1989 0.9947 Pullulan 20.5919 31.0420 10.6102 53.0509 Potassium sorbate 0.0772 0.1164 0.0398 0.1989 Purified water - - 65.8199 329.0995 Menthol 2.5740 3.8803 1.3263 6.6314 Peppermint Flavor 0.2579 0.3888 0.1329 0.6644 Cherry Flavor (Givudan) 0.2579 0.3888 0.1329 0.6644 Sour Cherry (IFF) 2.2350 3.3692 1.1516 5.7580 Warm Sensation (Mane) 0.5518 0.8318 0.2843 1.4216 Artificial Masking Agent 0.4139 0.6239 0.2133 1.0663 Flavor (Robertet) Succulence (FF) 0.2579 0.3888 0.1329 0.6644 FD&C Red #40 0.0098 0.0148 0.0050 0.0252 Polysorbate 80 NF 0.4504 0.6790 0.2321 1.1604 Atmos 300 0.4504 0.6790 0.2321 1.1604 Glycerine 1.9305 2.9102 0.9947 4.9735 Mannitol USP 2.5740 3.8803 1.3263 6.6314 Sucralose 1.8000 2.7135 0.9275 4.6373 Total 66.3357 100.0000 100.0000 500.0000 *Assuming that all water is evaporated 5 26 WO 2004/096192 PCT/IB2004/001270 EXAMPLE 5 The ingredients listed in Table 5 were combined to provide a consumable film of the present invention in accordance with the following procedure: 5 A) Dextromethorphan HBr was mixed and dissolved in 90% water at 759C to yield an aqueous phase. Amberlite IRP69 was added to the aqueous phase and stirred for about 4 to 5 hours at about 70-C to 802C. Pectin was added to the aqueous phase very slowly and mixed at a high mixing rate. The aqueous phase was allowed to cool to about 50-C and q.s. with water to replace loss due to 10 evaporation. Potassium sorbate and dye were then added to the aqueous phase and mixed thoroughly. B) The film-forming ingredients, xanthan gum, locust bean gum, carrageenan and PURE-COTE B793 were mixed together in a separate container to form a film forming mixture. 15 C) The film forming mixture was slowly added to the aqueous phase of A), followed by overnight mixing at a low mixing rate to provide a hydrated polymer gel. D) The flavorants, glycerine, olive oil, menthol, and surfactants were combined and mixed to dissolve in a separate container to yield an organic phase. E) Mannitol and sucralose were mixed together in the remaining 10% water 20 in a separate container. Succulence was then added to the resulting mixture and dissolved. F) The mixtures of steps D) and E) were added to the hydrated polymer gel and mixed uniformly to yield a final polymer gel mixture. The final polymer gel mixture was poured on a mold and cast to form a film of a desired thickness at room 27 WO 2004/096192 PCT/IB2004/001270 temperature. The film was dried under warm air and cut to a desired dimension (dictated by e.g., dosage and mouthfeel). Table 5 5 %w/w* %w/w Material mg/dose* %WW ww g/batch Material Dry Film Actual Batch g/batch Dextromethorphan HBr 15.0000 19.5740 10.6759 106.7593 Amberlite IRP69 16.0001 20.8790 11.3877 113.8771 Pectin USP 0.3499 0.4566 0.2490 2.4905 Xanthan Gum 0.0769 0.1003 0.0547 0.5470 Locust Bean Gum 0.0901 0.1175 0.0641 0.6409 Carrageenan 0.3860 0.5037 0.2747 2.7474 PURE-COTE B793 20.5919 26.8711 14.6559 146.5586 Potassium sorbate 0.0772 0.1008 0.0550 0.5498 Purified water - - 45.4586 454.5856 Menthol 2.5740 3.3589 1.8320 18.3202 Peppermint Flavor 0.2579 0.3366 0.1836 1.8357 Cherry Flavor (Givudan) 0.2579 0.3366 0.1836 1.8357 Sour Cherry (I FF) 2.2350 2.9165 1.5907 15.9070 Warm Sensation (Mane) 0.5518 0.7200 0.3927 3.9270 Artificial Masking Agent 0.4140 0.5402 0.2946 2.9463 Flavor (Robertet) Succulence (IFF) 0.2579 0.3366 0.1836 1.8357 FD&C Red #40 0.0099 0.0129 0.0070 0.0704 Polysorbate 80 NF 0.4505 0.5878 0.3206 3.2060 Atmos 300 0.4505 0.5878 0.3206 3.2060 Glycerine 8.7335 11.3966 6.2158 62.1585 Olive Oil 3.49934 4.5586 2.4863 24.8634 Mannitol USP 2.5740 3.3589 1.8320 18.3202 Sucralose 1.8001 2.3490 1.2812 12.8116 1000.000 Total 76.6324 100.0000 100.0000 1000.000 0 *Assuming that all water is evaporated 28 WO 2004/096192 PCT/IB2004/001270 EXAMPLE 6 The ingredients listed in Table 6 were combined to provide a consumable film of the present invention in accordance with the procedure example 5 with Amberlite 5 IRP64 being substituted by Amberlite IRP69. Table 6 ~%w/w %w/w* %w/w Material mg/dose* Dry Film Actual g/batch Batch Dextromethorphan HBr 15.0000 18.5409 10.3611 103.6107 Amberlite IRP69 16.0001 19.7771 11.0519 110.5186 Pectin USP 0.3499 0.4325 0.2417 2.4170 Xanthan Gum 0.0769 0.0950 0.0531 0.5309 Locust Bean Gum 0.0901 0.1113 0.0622 0.6220 Carrageenan 0.3860 0.4771 0.2666 2.6664 PURE-COTE B793 20.5919 25.4529 14.2236 142.2363 Potassium sorbate 0.0772 0.0955 0.0534 0.5335 Purified water - - 44.1179 451.1788 Menthol 2.5740 3.1817 1.7780 17.7799 Peppermint Flavor 0.2579 0.3188 0.1782 1.7816 Cherry Flavor (Givudan) 0.2579 0.3188 0.1782 1.7816 Sour Cherry (IFF) 2.2350 2.7626 1.5438 15.4379 Warm Sensation (Mane) 0.5518 0.6820 0.3811 3.8112 Artificial Masking Agent 0.4140 0.5117 0.2859 2.8594 Flavor (Robertet) Succulence (IFF) 0.2579 0.3188 0.1782 1.7816 FD&C Red #40 0.0099 0.0122 0.0068 0.0684 Polysorbate 80 NF 0.4505 0.5568 0.3111 3.1114 Atmos 300 0.4505 0.5568 0.3111 3.1114 Glycerine 11.6446 14.3935 8.0434 80.4337 Olive Oil 4.8519 5.9973 3.3514 33.5140 Mannitol USP 2.5740 3.1817 1.7780 17.7799 Sucralose 1.8001 2.2250 1.2434 12.4337 Total 80.9021 100.0000 100.0000 1000.0000 *Assuming that all water is evaporated 29 WO 2004/096192 PCT/IB2004/001270 EXAMPLE 7 The ingredients listed in Table 7 were combined to provide a consumable film of the present invention in accordance with the following procedure: 5 A) Dextromethorphan HBr was mixed and dissolved in 90% water at 75°C to yield an aqueous phase. Amberlite IRP69 was added to the aqueous phase and stirred for about 4 to 5 hours at about 70LC to 8 02C. Pectin dispersed in glycerine was added very slowly to the aqueous phase and mixed at a high mixing rate. The aqueous phase was allowed to cool to about 50 2 C and q.s. with water to replace loss 10 due to evaporation. The dye was then added to the aqueous phase and mixed thoroughly. B) The film-forming ingredients, xanthan gum, locust bean gum, carrageenan and pullulan were mixed together in a separate container to form a film forming mixture. 15 C) The film forming mixture was slowly added to the aqueous phase of A), followed by overnight mixing at a low mixing rate to provide a hydrated polymer gel. D) The flavorants, menthol, and surfactants were combined and mixed to dissolve in a separate container to yield an organic phase. E) Mannitol and sucralose were mixed together in the remaining 10% water 20 in a separate container. Succulence was then added to the resulting mixture and dissolved. F) The mixtures of steps D) and E) were added to the hydrated polymer gel and mixed uniformly to yield a final polymer gel mixture. The final polymer gel mixture was poured on a mold and cast to form a film of a desired thickness at room 30 WO 2004/096192 PCT/IB2004/001270 temperature. The film was dried under warm air and cut to a desired dimension (dictated by e.g., dosage and mouthfeel). Table 7 Material mg/dose* %w/w* %w/w G/batch Dry Film Actual Batch Dextromethorphan HBr 15.0000 22.5510 7.7080 19.2699 Amberlite IRP64 16.0000 24.0544 8.2218 20.5545 Pectin USP 0.3500 0.5262 0.1799 0.4496 Xanthan Gum 0.0769 0.1156 0.0395 0.0988 Locust Bean Gum 0.0901 0.1355 0.0463 0.1157 Carrageenan 0.3861 0.5805 0.1984 0.4960 Pullulan 20.5919 30.9579 10.5814 26.4536 Potassium sorbate 0.0772 0.1161 0.0397 0.0992 Purified water - - 65.8199 164.5498 Menthol 2.5740 3.8698 1.3227 3.3067 Peppermint Flavor 0.2579 0.3877 0.1325 0.3313 Cherry Flavor (Givudan) 0.2579 0.3877 0.1325 0.3313 Sour Cherry (1FF) 2.2350 3.3601 1.1485 2.8712 Warm Sensation (Mane) 0.5518 0.8296 0.2835 0.7089 Artificial Masking Agent 0.4139 0.6223 0.2127 0.5317 Flavor (Robertet) 0.4139 0.6223 0.2127 0.5317 Succulence (IFF) 0.2579 0.3877 0.1325 0.3313 Carmine 0.1900 0.2856 0.0976 0.2441 Polysorbate 80 NF 0.4504 0.6771 0.2314 0.5786 Atsurf 596K 0.4504 0.6771 0.2314 0.5786 Glycerine 1.9305 2.9023 0.9920 2.4800 Mannitol USP 2.5740 3.8698 1.3227 3.3067 Sucralose 1.8000 2.7061 0.9250 2.3124 Total 66.5159 100.0000 100.0000 250.0000 *Assuming that all water is evaporated 5 31 WO 2004/096192 PCT/IB2004/001270 EXAMPLE 8 The ingredients listed in Table 8 were combined to provide a consumable film of the present invention in accordance with the procedure described in Example 7. 5 Table 8 Material mg/dose* %w/w* %w/ g/batch Dry Film Actual Batch Dextromethorphan HBr 15.0000 22.5772 7.7169 38.5846 Amberlite IRP64 16.0000 24.0823 8.2314 41.1569 Pectin USP 0.3500 0.5268 0.1801 0.9003 Xanthan Gum 0.0769 0.1157 0.0396 0.1978 Locust Bean Gum 0.0901 0.1356 0.0464 0.2318 Carrageenan 0.3861 0.5811 0.1986 0.9932 Pullulan 20.5919 30.9938 10.5937 52.9686 Carmine 0.1900 0.2860 0.0977 0.4887 Purified water - - 65.8199 329.0995 Menthol 2.5740 3.8742 1.3242 6.6211 Peppermint Flavor 0.2579 0.3882 0.1327 0.6634 Cherry Flavor (Givudan) 0.2579 0.3882 0,1327 0.6634 Sour Cherry (IFF) 2.2350 3.3640 1.1498 5.7491 Warm Sensation (Mane) 0.5518 0.8305 0.2839 1.4194 Artificial Masking Agent Artificial Masking Agent 0.4139 0.6230 0.2129 1.0647 Flavor (Robertet) Succulence (IFF) 0.2579 0.3882 0.1327 0.6634 Polysorbate 80 NF 0.4504 0.6779 0.2317 1.1586 Atmos 300 0.4504 0.6779 0.2317 1.1586 Glycerine 1.9305 2.9057 0.9932 4.9658 Mannitol USP 2.5740 3.8742 1.3242 6.6211 Sucralose 1.8000 2.7093 0.9260 4.6301 Total 66.4387 100.0000 100.0000 500.0000 *Assuming that all water is evaporated 32 WO 2004/096192 PCT/IB2004/001270 EXAMPLE 9 The ingredients listed in Table 9 were combined to provide a consumable film of the present invention in accordance with the procedure described in Example 7 5 absent the resin. Table 9 Material mg/dose* %w/w* %w/w g/batch Dry Film Actual Batch Dextromethorphan 10.9900 18.3460 5.5038 27.5189 (Spectrum) Pectin USP 0.5250 0.8764 0.2629 1.3146 Carmine 0.1900 0.3172 0.0952 0.4758 Xanthan Gum 0.1154 0.1926 0.0578 0.2888 Locust Bean Gum 0.1352 0.2256 0.0677 0.3384 Carrageenan 0.5792 0.9668 0.2900 1.4502 Pullulan 30.8879 51.5621 15.4686 77.3431 Purified water - - 70 350.0000 Menthol 2.5740 4.2969 1.2891 6.4453 Peppermint Flavor 0.8000 1.3355 0.4006 2.0032 Cherry Flavor (Givudan) 0.8000 1.3355 0.4006 2.0032 Sour Cherry (IFF) 2.2350 3.7310 1.1193 5.5964 Warm Sensation (Mane) 0.8000 1.3355 0.4006 2.0032 Artificial Masking Agent Artificial Masking Agent 0.8000 1.3355 0.4006 2.0032 Flavor (Robertet) Succulence (IFF) 0.2579 0.4305 0.1292 0.6458 Polysorbate 80 NF 0.4504 0.7519 0.2256 1.1278 Atmos 300 0.4504 0.7519 0.2256 1.1278 Glycerine 2.0400 3.4054 1.0216 5.1082 Sucralose 2.7000 4.5072 1.3522 6.7608 Mannitol USP 2.5740 4.2969 1.2891 6.4453 Total 59.9042 100.0000 100.0000 500.0000 *Assuming that all water is evaporated 33 WO 2004/096192 PCT/IB2004/001270 EXAMPLE 10 The ingredients listed in Table 10 were combined to provide a consumable film of the present invention in accordance with the procedure described in Example 5 7. Table 10 Material mg/dose* %w/w* %w/w g/batch Dry Film Actual Batch Dextromethorphan (milled) 10.9900 26.6157 9.2695 18.5390 Amberlite IRP69 2.4000 5.8123 2.0243 4.04486 Pectin USP 0.2698 0.6534 0.2276 0.4551 Carmine 0.1464 0.3546 0.1235 0.2470 Xanthan Gum 0.0594 0.1439 0.0501 0.1002 Locust Bean Gum 0.0694 0.1681 0.0585 0.1171 Carrageenan 0.2975 0.7205 0.2509 0.5019 Pullulan 15.8694 38.4327 13.3850 26.7701 Purified water - 65.1728 130.3456 Menthol 2.5740 6.2337 2.1710 4.3421 Peppermint Flavor 0.1987 0.4812 0.1676 0.3352 Cherry Flavor (Givudan) 0.1987 0.4812 0.1676 0.3352 Sour Cherry (IFF) 1.7225 4.1716 1.4528 2.9057 Warm Sensation (Mane) 0.4252 1.0298 0.3586 0.7173 Artificial Masking Agent Artificial Masking Agent 0.3190 0.7726 0.2691 0.5381 Flavor (Robertet) Succulence (IFF) 0.1987 0.4812 0.1676 0.3352 Polysorbate 80 NF 0.3470 0.8404 0.2927 0.5854 Atmos 300 0.3470 0.8404 0.2927 0.5854 Glycerine 1.4877 3.6029 1.2548 2.5096 Mannitol USP 1.9837 4.8041 1.6732 3.3463 Sucralose 1.3873 3.3598 1.1701 2.3402 Total 41.2914 100.0000 100.0000 200.0000 *Assuming that all water is evaporated 34 WO 2004/096192 PCT/IB2004/001270 EXAMPLE 11 The ingredients listed in Table 11 were combined to provide a consumable film of the present invention in accordance with the following procedure: 5 A) Potassium sorbate and dye were mixed in 80% water. B) The film-forming ingredients, xanthan gum, locust bean gum, carrageenan and Pure-Cote B793 were mixed together in a separate container to form a film forming mixture. C) The film forming mixture was slowly added to the mixture of A), followed 10 by overnight mixing at a low mixing rate to form a hydrated polymer gel. D) Mannitol and sucralose were mixed together with remaining 20% of water in a separate container, and then added to the hydrated polymer gel and mixed well. E) Milled famotidine HCI was added to the hydrated polymer gel and mixed thoroughly. 15 F) The flavorants, glycerine, olive oil and surfactants were combined and mixed thoroughly in a separate container. G) The resulting mixture of step F) was added to the hydrated polymer gel and mixed uniformly to yield a final polymer gel mixture. The final polymer gel mixture was poured on a mold and cast to form a film of a desired thickness at room 20 temperature. The film was dried under warm air and cut to a desired dimension (dictated by e.g., dosage and mouthfeel). 35 WO 2004/096192 PCT/IB2004/001270 Table 11 %w/w %w/w* %w/w Material mg/dose* Dry Film Actual g/batch Batch Famotidine 10.0000 15.2065 5.3223 106.4453 Xanthan Gum 0.1154 0.1754 0.0614 1.2278 Locust Bean Gum 0.1352 0.2055 0.0719 1.4386 Carrageenan 0.5792 0.8807 0.3082 6.1648 Pure-Cote B793 30.8879 46.9695 16.4393 328.7865 Potassium sorbate 0.1158 0.1761 0.0616 1.2326 Purified water - - 65.0000 1300.0000 Vanilla Mint Flavor (IFF) 2.0000 3.0413 1.0645 21.2891 Polysorbate 80 NF 0.6756 1.0273 0.3596 7.1914 Atsurf 596K 0.6756 1.0273 0.3596 7.1914 Glycerine 10.0000 15.2065 5.3223 106.4453 Olive oil 4.0000 6.0826 2.1289 42.5781 FD&C Blue #1 0.0160 0.0243 0.0085 0.1703 Mannitol USP 3.8610 5.8712 2.0549 41.0985 Sucralose 2.7000 4.1057 1.4370 28.7402 Total 65.7615 100.0000 100.0000 2000.0000 *Assuming that all water is evaporated 36 WO 2004/096192 PCT/IB2004/001270 EXAMPLE 12 The ingredients listed in Table 12 were combined to provide a consumable film of the present invention in accordance with the procedure described in Example 5 11 with the PURE-COTE B793 substituted by Tapioca Starch J474. Table 12 Material mg/dose* %w/w* %w/w g/batch Dry Film Actual Batch batch Famotidine 10.0000 9.7503 4.4512 26.6184 Xanthan Gum 0.1154 0.1125 0.0513 0.3070 Locust Bean Gum 0.1352 0.1318 0.0602 0.3597 Carrageenan 0.5792 0.5647 0.2578 1.5416 Tapioca Starch J474 67.6870 65.9970 30.1291 180.1720 Potassium sorbate 0.1158 0.1129 0.0515 0.3082 Purified water - - 54.3478 324.9998 Vanilla Mint Flavor (IFF) 2.0000 1.9501 0.8902 5.237 Polysorbate 80 NF 0.6756 0.6587 0.3007 1.7983 Atsurf 596K 0.6756 0.6587 0.3007 1.7983 Glycerine 10.0000 9.7503 4.4512 26.6184 Olive oil 4.0000 3.9001 1.7805 10.6474 FD&C Blue #1 0.0160 0.0156 0.0071 0.0426 Mannitol USP 3.8610 3.7646 1.7186 10.2774 Sucralose 2.7000 2.6326 1.2018 7.1870 Total 102.5607 100.0000 100.0000 598.0000 *Assuming that all water is evaporated 37 WO 2004/096192 PCT/IB2004/001270 EXAMPLE 13 The ingredients listed in Table 13 were combined to provide a consumable film of the present invention in accordance with the following procedure: 5 A) The dye, copper gluconate, acesulfame potassium salt, and aspartame were dissolved in water and mixed for about 30 minutes to yield an aqueous phase. B) The film-forming ingredients, xanthan gum, locust bean gum, carrageenan and pullulan were mixed together in a separate container to form a film forming mixture. 10 C) The film forming mixture was slowly added to the aqueous phase of A), followed by overnight mixing at a low mixing rate to provide a hydrated polymer emulsion. D) The mint flavor, Physcool, thymol, methyl salicylate, eucalyptol and menthol were combined and mixed to dissolve in a separate container to yield an 15 organic phase. E) The organic phase was added to the hydrated polymer emulsion and mixed uniformly to yield a final polymer emulsion mixture. The final polymer emulsion mixture was poured on a mold and cast to form a film of a desired thickness at room temperature. The film was dried under warm air and cut to a 20 desired dimension (dictated by e.g., dosage and mouthfeel). 38 WO 2004/096192 PCT/IB2004/001270 Table 13 Material %w/w* %w/w Material %WW WW g/batch Dry Film Actual Batch g/batch Xanthan Gum 0.1393 0.0344 0.1722 Locust Bean Gum 0.2786 0.0689 0.3444 Carrageenan 1.3929 0.3444 1.7222 Pullulan 66.9165 16.5475 82.7374 FD&C Green No. 3 0.0106 0.0026 0.0131 Copper gluconate 1.4459 0.3575 1.7877 Acesulfame Potassium 1.8083 0.4472 2.2359 Aspartame 5.7875 1.4312 7.1558 Purified water - 75.2714 376.3571 Mint Flavor 10.8500 2.6830 13.4152 Physcool/ Mint Flavor 0.3625 0.0896 0.4482 Thymol 0.5295 0.1309 0.6546 Methyl salicylate 0.7575 0.1873 0.9367 Eucalyptol 0.7575 0.1873 0.9367 Menthol 8.9635 2.2165 11.0827 Total 100.0000 100.0000 500.0000 *Assuming that all water is evaporated EXAMPLE 14 5 The ingredients listed in Table 14 were combined to provide a consumable film of the present invention in accordance with the following procedure: A) Dextromethorphan HBr was mixed and dissolved in 90% water at 75-C to 10 yield an aqueous phase. Sodium bicarbonate was added and mixed for about 1 hour. Amberlite IRP69 was added to the aqueous phase and stirred for about 2 hours at about 70LC to 809C. The resulting mixture was allowed to cool to 50LC and q.s. with water for losses due to evaporation. The dye was then added to the aqueous phase and mixed thoroughly. 39 WO 2004/096192 PCT/IB2004/001270 B) The film-forming ingredients, xanthan gum, locust bean gum, carrageenan and pullulan were added slowly and rapidly mixed together in a separate container to form a film forming mixture. The mixture was mixed overnight at a low speed. Pectin dispersed in glycerine was added very slowly to the film forming mixture and 5 mixed at a high mixing rate. C) The film forming mixture was slowly added to the aqueous phase of A), followed by overnight mixing at a low mixing rate to provide a hydrated polymer gel. D) In another container the remaining 10% water was added to dissolve mannitol and sucralose. Succulence was then added and mixed to dissolve. The 10 resulting mixture was added to the hydrated polymer gel. E) The flavorants, menthol, and surfactants were combined and mixed to dissolve in a separate container to yield an organic phase. F) The mixtures of steps D) and E) were added together and mixed uniformly to yield a final polymer gel mixture. The final polymer gel mixture was poured on a 15 mold and cast to form a film of a desired thickness at room temperature. The film was dried under warm air and cut to a desired dimension (dictated by e.g., dosage and mouthfeel). 40 WO 2004/096192 PCT/IB2004/001270 Table 14 %w/w* %w/w Material mg/dose* Dry Film Actual g/batch Batch Dextromethorphan HBr 15.0000 27.3219 9.6903 484.5135 Amberlite IRP69 8.0000 14.5717 5.1681 258.4072 Pectin USP 0.2698 0.4914 0.1743 8.7148 Sodium bicarbonate Sodium bicarbonate 4.0000 7.2858 2.5841 129.2036 anhydrous Carmine 0.1464 0.2667 0.0946 4.7289 Xanthan Gum 0.0594 0.1082 0.0384 1.91187 Locust Bean Gum 0.0694 0.1264 0.0448 2.2417 Carrageenan 0.2975 0.5419 0.1922 9.6095 Pullulan 15.8690 28.9047 10.2517 512.5830 Purified water - - 64.5329 3226.6450 Menthol 2.5740 4.6884 1.6629 83.1425 Peppermint Flavor 0.1987 0.3619 0.1284 6.4182 Cherry Flavor (Givudan) 0.1987 0.3619 0.1284 6.4182 Cherry Flavor Blend (IFF) 1.7225 3.1375 1.1128 55.6383 Warm Sensation (Mane) 0.4252 0.7745 0.2747 13.7343 Artificial Masking Agent Artificial Masking Agent 0.3190 0.5810 0.2061 10.3040 Flavor (Robertet) Succulence (IFF) 0.1987 0.3619 0.1284 6.4182 Polysorbate 80 NF 0.3470 0.6320 0.2242 11.2084 Atmos 300 0.3470 0.6320 0.2242 11.2084 Glycerine 1.4877 2.7100 0.9611 48.0573 Mannitol USP 1.9837 3.6132 1.2815 64.0753 Sucralose 1.3873 2.5269 0.8962 44.8110 Total 54.9011 100.0000 100.0000 50000.0000 *Assuming that all water is evaporated 5 41 WO 2004/096192 PCT/IB2004/001270 EXAMPLE 15 The ingredients listed in Table 15 were combined to provide a consumable film of the present invention in accordance with the following procedure: 5 A) Dextromethorphan HBr was mixed and dissolved in water at 50LC to yield an aqueous phase. Potassium sorbate and the sweeteners were added to the aqueous phase and stirred. Titanium dioxide was then added and the mixture was further stirred. B) The film-forming ingredients, xanthan gum, locust bean gum, carrageenan 10 and pullulan were mixed together in a separate container to form a film forming mixture. C) The film forming mixture was slowly added to the aqueous phase of A) while mixing rapidly. The resulting mixture was mixed overnight at a low mixing rate to provide a hydrated polymer gel. 15 D) Glycerin and olive oil were mixed in a separate container. Menthol and mono ammonium glycyrrhizinate were added to the glycerin/olive oil mixture and heated to dissolve at 459 C. Physcool, polysorbate 80 and Atmos 300 were then added to the resulting mixture and further mixed to yield an organic phase. E) The mixture of step D) was added to the hydrated polymer gel and mixed 20 uniformly to yield a final polymer gel mixture. Cherry flavor was then added to the polymer gel mixture. The final polymer gel mixture was poured on a mold and cast to form a film of a desired thickness at room temperature. The film was dried under warm air and cut to a desired dimension (dictated by e.g., dosage and mouthfeel). 42 WO 2004/096192 PCT/IB2004/001270 Table 15 Material mg/dose* %/* %w/w g/batch Dry Film Actual Batch g Dextromethorphan Coated 25.0000 27.7778 8.4515 0.2770 (60% dex) 25.0000 27.7778 8.4515 0.2770 Xanthan Gum 0.1625 0.1805 0.0549 0.0018 Locust Bean Gum 0.1896 0.2106 0.0641 0.0021 Carrageenan 0.8124 0.9027 0.2746 0.0090 Pullulan 43.3286 48.1429 14.6478 0.4800 Potassium Sorbate 0.1625 0.1805 0.0549 0.0018 Acesulfame Potassium 1.3540 1.5045 0.4577 0.0150 Salt 1.3540 1.5045 0.4577 0.0150 Aspartame NF 3.7913 4.2125 1.2817 0.0420 Purified water --- --- 69.5744 2.2799 Physcool 0.2708 0.3009 0.0915 0.0030 Menthol 2.7080 3.0089 0.9155 0.0300 Cherry Flavor (Givudan) 0.1354 0.1504 0.0458 0.0015 Mono ammonium glycyrrhizinate (MAG) 0.0271 0.0301 0.0092 0.0003 Polysorbate 80 NF 0.9478 1.0531 0.3204 0.0105 Atmos 300 0.9478 1.0531 0.3204 0.0105 Glycerine 8.1241 9.0268 2.7465 0.0900 Olive Oil 1.3540 1.5045 0.4577 0.0150 FD&C green #3 0.0070 0.0078 0.0024 0.0001 Titanium Dioxide 0.6770 0.7522 0.2289 0.0075 Total 90.0000 100.0000 100.0000 3.2770 *Assuming that all water is evaporated 43 WO 2004/096192 PCT/IB2004/001270 EXAMPLE 16 The ingredients listed in Table 16 were combined to provide a consumable film of the present invention in accordance with the following procedure: 5 A) Dextromethorphan HBr was mixed and dissolved in water at 75-C to yield an aqueous phase. Amberlite IRP69 was added to the aqueous phase and stirred for about 2 hours at about 70-C to 809C. The resulting mixture was allowed to cool to 50-C and q.s. with water for losses due to evaporation. The sweeteners and 10 potassium sorbate were then added to the aqueous phase and mixed thoroughly. B) The film-forming ingredients, xanthan gum, locust bean gum, carrageenan and pullulan were added slowly into a separate container, and rapidly mixed together to form a film forming mixture. The mixture was mixed overnight at a low speed. C) The film forming mixture was slowly added to the aqueous phase of A), 15 followed by overnight mixing at a low mixing rate to provide a hydrated polymer gel. D) In another container, the alcohol was mixed with menthol. Physcool was then added to the resulting mixture and mixed. Mono ammonium glycyrrhizinate, polysorbate 80, Atmos 300 and flavors were added to the mixture and further mixed to yield uniformity. Glycerine and mannitol were added to the mixture and mixed. 20 E) The mixture of step D) was added to the hydrated polymer gel of step C) and mixed uniformly to yield a final polymer gel mixture. The final polymer gel mixture was poured on a mold and cast to form a film of a desired thickness at room temperature. The film was dried under warm air and cut to a desired dimension (dictated by e.g., dosage and mouthfeel). 44 WO 2004/096192 PCT/IB2004/001270 Table 16 Material Mg/dose* %w/w* %w/w g/batch Dry Film Actual Batch Dextromethorphan HBr 15.0000 21.4286 9.2666 11.4615 Amberlite IRP69 16.0000 22.8571 9.8843 12.2256 Xanthan Gum 0.0944 0.1348 0.0485 0.0600 Locust Bean Gum 0.1101 0.1573 0.0566 0.070 Carrageenan 0.4718 0.6740 0.2425 0.3000 Pullulan 25.1613 35.9447 12.9359 16.0000 Potassium Sorbate 0.0944 0.1348 0.0485 0.0600 Acesulfame Potassium Salt 0.7863 1.1233 0.4042 0.5000 Aspartame NF 2.2016 3.1452 1.1319 1.4000 Purified water --- 56.7561 70.2000 Alcohol USP ----- 4.0425 5.000 Physcool 0.1573 0.2247 0.0808 0.1000 Menthol 2.3589 3.3698 1.2127 1.5000 Peppermint Flavor 0.1573 0.2247 0.0808 0.1000 Raspberry Flavor (Givudan) 0.7863 1.1233 0.4042 0.5000 Mono ammonium crrhizinate MAG 0.0157 0.0225 0.0081 0.0100 glycyrrhizinate (MAG) Polysorbate 80 NF 0.5504 0.7863 0.2830 0.3500 Atmos 300 0.5504 0.7863 0.2830 0.3500 Glycerine 2.3589 3.3698 1.2127 1.5000 Mannitol USP 3.1452 4.4931 1.6170 2.0000 Total 70.0000 100.0000 100.0000 123.6872 *Assuming that all water is evaporated The forgoing discussion discloses and describes merely exemplary embodiments of the present invention. One skilled in the art will readily recognize 5 from such discussion, and from the accompanying claims, that various changes, modifications, and variations can be made therein without departing from the spirit and scope of the invention as defined in the following claims. 45
    权利要求:
    Claims (13)
    [1] 1. A consumable film adapted to adhere to and dissolve in the oral cavity of a warm-blooded animal including humans, comprising at least one water soluble 5 polymer, a taste masking effective amount of a sucralose, and a pharmaceutically active agent.
    [2] 2. The consumable film of claim 1, further comprising a second sweetener selected from the group consisting of saccharin, aspartame, xylitol, acesulfame 10 potassium and mixtures thereof.
    [3] 3. The consumable film of claim 1 wherein the sweetener is present in the amount of from about 0.1% to 10% by weight based on the total weight of the consumable film. 15 4'. The consumable film of claim 1 wherein the pharmaceutically active agent is selected from the group consisting of aspirin, acetaminophen, ibuprofen, ketoprofen, diflunisal, fenoprofen calcium, naproxen, tolmetin sodium, indomethacin, flurbiprofen sodium, celecoxib, valdecoxib, rofecoxib and mixtures thereof. 20
    [4] 5. The consumable film of claim 1 wherein the pharmaceutically active agent is valdecoxib. 46 WO 2004/096192 PCT/IB2004/001270
    [5] 6. The consumable film of claim 1 wherein the pharmaceutically active agent is selected from the group consisting of benzonatate, caramiphen edisylate, menthol, dextromethorphan hydrobromide, chlophedianol hydrochloride and mixtures thereof. 5
    [6] 7. The consumable film of claim 1 wherein the pharmaceutically active agent is selected from the group consisting of pseudoephedrine hydrochloride, phenylepherine, phenylpropanolamine, pseudoephedrine sulfate and mixtures thereof. 10
    [7] 8. The consumable film of claim 1 wherein the pharmaceutically active agent is selected from the group consisting of brompheniramine maleate, chlorpheniramine maleate, carbinoxamine maleate, clemastine fumarate, dexchlorpheniramine maleate, diphenhydramine hydrochloride, azatadine maleate, 15 diphenhydramine citrate, diphenylpyraline hydrochloride, doxylamine succinate, promethazine hydrochloride, pyrilamine maleate, tripelennamine citrate, triprolidine hydrochloride, acrivastine, loratadine, . brompheniramine, dexbropheniramine, fexofenadine, cetirizine and mixtures thereof. 20 9. The consumable film of claim 1 wherein the pharmaceutically active agent is selected from the group consisting of famotidine, ranitidine and mixtures thereof. 47 WO 2004/096192 PCT/IB2004/001270
    [8] 10. The consumable film of claim 1 wherein the at least one water soluble polymer is selected from the group consisting of pullulan, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, 5 tragacanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methylmethacrylate copolymers, carboxyvinyl polymers, amylose, high amylose starch, hydroxypropylated high amylose starch, dextrin, pectin, chitin, chitosan, levan, elsinan, collagen, gelatin, zein, gluten, soy protein isolate, whey protein isolate, casein and mixtures thereof. 10
    [9] 11. The consumable film of claim 1 wherein said at least one water soluble polymer is pullulan.
    [10] 12. The consumable film of claim 1 wherein the pharmaceutically active 15 agent is at least one essential oil selected from the group consisting of thymol, menthol, methyl salicylate (wintergreen oil), eucalyptol, carvacrol, camphor, anethole, carvone, eugenol, isoeugenol, limonene, osimen, n-decyl alcohol, citronel, a-salpineol, methyl acetate, citronellyl acetate, methyl eugenol, cineol, linalool, ethyl linalaol, safrola vanillin, spearmint oil, peppermint oil, lemon oil, orange oil, sage oil, .20 rosemary oil, cinnamon oil, pimento oil, laurel oil, cedar leaf oil, gerianol, verbenone, anise oil, bay oil, benzaldehyde, bergamot oil, bitter almond, chlorothymol, cinnamic aldehyde, citronella oil, clove oil, coal tar, eucalyptus oil, guaiacol, lavender oil, mustard oil, phenol, phenyl salicylate, pine oil, pine needle oil, sassafras oil, spike 48 WO 2004/096192 PCT/IB2004/001270 lavender oil, storax, thyme oil, tolu balsam, terpentine oil, clove oil, and combinations thereof.
    [11] 13. The consumable film of claim 12 wherein the at least one essential oil 5 is selected from the group consisting of thymol, methyl salicylate, eucalyptol, menthol and mixtures thereof.
    [12] 14. The consumable film of claim 1, wherein said film is in the form of a single layer. 10
    [13] 15. A method for delivering a pharmaceutically active agent within the oral cavity of a warm-blooded animal including humans comprising administering the consumable film of claim 1 to the oral cavity. 49
    类似技术:
    公开号 | 公开日 | 专利标题
    US20030211136A1|2003-11-13|Fast dissolving orally consumable films containing a sweetener
    CA2521509C|2009-06-23|Fast dissolving orally consumable films containing pharmaceutically active agents
    US20040247648A1|2004-12-09|Fast dissolving orally consumable films containing a modified starch for improved heat and moisture resistance
    US7025983B2|2006-04-11|Fast dissolving orally consumable films
    WO2008098195A2|2008-08-14|Film comprising nitroglycerin
    CA2520986C|2007-11-13|Physiological compatible film
    CA2572461C|2009-12-01|Physiological compatible film
    BR9917782B1|2011-10-18|method for the preparation of a physiologically compatible film.
    同族专利:
    公开号 | 公开日
    AR044077A1|2005-08-24|
    PA8601401A1|2005-03-28|
    CL2004000837A1|2005-03-18|
    GT200400080A|2005-03-03|
    TW200510006A|2005-03-16|
    MXPA05011508A|2005-12-15|
    US20080020024A1|2008-01-24|
    PE20050379A1|2005-05-17|
    ZA200508118B|2007-01-31|
    UY28285A1|2004-11-30|
    JP2006524675A|2006-11-02|
    BRPI0409715A|2006-05-02|
    US20030211136A1|2003-11-13|
    EP1635796A1|2006-03-22|
    CA2521735A1|2004-11-11|
    CN1809343A|2006-07-26|
    WO2004096192A1|2004-11-11|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US35841A||1862-07-08||Improvement in chamber-buckets |
    US131990A||1872-10-08||Improvement in rotary churns |
    US99691A||1870-02-08||Improved carriage-wheel |
    US2193342A|1938-10-15|1940-03-12|Kenneth A Price|Domestic mold for frozen stick confections|
    US3008008A|1957-05-16|1961-11-07|North Electric Co|Automatic telephone system|
    GB1142325A|1965-05-14|1969-02-05|Higham Stanley Russell|Means for administering drugs|
    DE2012775C3|1970-03-18|1973-10-04|V.P. Variopharm Gmbh Herstellung Und Vertrieb Pharmazeutischer, Kosmetischer Und Chemischer Erzeugnisse, 6656 Einoed|Ointment foils and process for their manufacture|
    US4197289A|1975-12-15|1980-04-08|Hoffmann-La Roche Inc.|Novel dosage forms|
    US4406883A|1976-07-23|1983-09-27|Merrell Dow Pharmaceuticals Inc.|Controlled release suppositories consisting essentially of a linear polymer particularly, polyvinyl pyrrolidones|
    US4562020A|1982-12-11|1985-12-31|Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo|Process for producing self-supporting glucan film|
    US4795436A|1983-11-14|1989-01-03|Bio-Mimetics, Inc.|Bioadhesive composition and method of treatment therewith|
    JPH0549705B2|1984-04-14|1993-07-27|Hayashibara Biochem Lab||
    IL78826A|1986-05-19|1991-05-12|Yissum Res Dev Co|Precursor composition for the preparation of a biodegradable implant for the sustained release of an active material and such implants prepared therefrom|
    DE3630603C2|1986-09-09|1989-06-22|Desitin Arzneimittel Gmbh, 2000 Hamburg, De||
    JPH0739508B2|1986-11-11|1995-05-01|株式会社林原生物化学研究所|Pullulan / polyethylene glycol aggregate, its production method and use|
    US4820506A|1987-05-01|1989-04-11|Research Foundation, State University Of New York|Salivary stimulant|
    US4975426A|1987-06-08|1990-12-04|Analgesic Associates|Cough/cold mixtures comprising non-sedating antihistamine drugs|
    US5047244A|1988-06-03|1991-09-10|Watson Laboratories, Inc.|Mucoadhesive carrier for delivery of therapeutical agent|
    DE3827561C1|1988-08-13|1989-12-28|Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De||
    US5013716A|1988-10-28|1991-05-07|Warner-Lambert Company|Unpleasant taste masking compositions and methods for preparing same|
    US5354551A|1989-10-14|1994-10-11|Desitin Arzneimittel Gmbh|Oral and dental hygiene preparation|
    US5284659A|1990-03-30|1994-02-08|Cherukuri Subraman R|Encapsulated flavor with bioadhesive character in pressed mints and confections|
    DE4018247C2|1990-06-07|1992-05-14|Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De||
    US5141961A|1991-06-27|1992-08-25|Richrdson-Vicks Inc.|Process for solubilizing difficulty soluble pharmaceutical actives|
    US5411945A|1992-08-29|1995-05-02|Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo|Pullulan binder and its uses|
    US5294433A|1992-04-15|1994-03-15|The Procter & Gamble Company|Use of H-2 antagonists for treatment of gingivitis|
    US5286502A|1992-04-21|1994-02-15|Wm. Wrigley Jr. Company|Use of edible film to prolong chewing gum shelf life|
    JP3232488B2|1992-08-20|2001-11-26|株式会社林原生物化学研究所|High content of pullulan, its production method and use|
    EP0717761A4|1993-08-19|1998-01-07|Cygnus Therapeutic Systems|Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity|
    US5536263A|1994-03-30|1996-07-16|Lectec Corporation|Non-occulusive adhesive patch for applying medication to the skin|
    US5529783A|1994-12-19|1996-06-25|Mcneil-Ppc, Inc.|Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan|
    US5641512A|1995-03-29|1997-06-24|The Procter & Gamble Company|Soft gelatin capsule compositions|
    EP0803243B1|1996-04-24|2003-03-19|Pfizer Inc.|Cyclodextrins and phenolic compounds in dental products|
    DE19646392A1|1996-11-11|1998-05-14|Lohmann Therapie Syst Lts|Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery|
    US6132702A|1998-02-27|2000-10-17|The Procter & Gamble Company|Oral care compositions comprising chlorite and methods|
    US6596298B2|1998-09-25|2003-07-22|Warner-Lambert Company|Fast dissolving orally comsumable films|
    US6340473B1|1999-07-07|2002-01-22|R.P. Scherer Technologies, Inc.|Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same|
    US20020131990A1|2000-11-30|2002-09-19|Barkalow David G.|Pullulan free edible film compositions and methods of making the same|
    US6391886B1|2000-12-04|2002-05-21|The Procter & Gamble Company|Oral compositions having improved consumer aesthetics|
    US20020193342A1|2001-05-09|2002-12-19|Hamman John P.|Modifying undesirable tastes|
    WO2003007734A1|2001-07-19|2003-01-30|San-Ei Gen F.F.I., Inc.|Flavor-improving compositions and application thereof|
    CA2455939C|2001-07-31|2011-03-22|Wyeth Llc|Sucralose formulations to mask unpleasant tastes|
    US6419903B1|2001-08-20|2002-07-16|Colgate Palmolive Company|Breath freshening film|
    AU2002347165B2|2001-12-11|2008-05-29|Ceapro Inc.|Cereal beta glucan compositions, methods of preparation and uses thereof|US6596298B2|1998-09-25|2003-07-22|Warner-Lambert Company|Fast dissolving orally comsumable films|
    US7067116B1|2000-03-23|2006-06-27|Warner-Lambert Company Llc|Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1|
    MXPA05005243A|2002-11-14|2006-03-10|Innozen Inc|Edible film for relief of cough or symptoms associated with pharyngitis.|
    US8999372B2|2002-11-14|2015-04-07|Cure Pharmaceutical Corporation|Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use|
    CN1764436A|2003-03-26|2006-04-26|宝洁公司|Rapidly dissolving edible film compositions with improved film strength and stability|
    US20040191302A1|2003-03-28|2004-09-30|Davidson Robert S.|Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films|
    US20040202717A1|2003-04-08|2004-10-14|Mehta Atul M.|Abuse-resistant oral dosage forms and method of use thereof|
    JP2006525308A|2003-05-02|2006-11-09|ワーナー−ランバートカンパニーリミティドライアビリティーカンパニー|Fast-dissolving oral consumable film containing modified starch with improved heat and moisture resistance|
    GB0312419D0|2003-05-30|2003-07-02|Boots Healthcare Int Ltd|Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess|
    GB0312425D0|2003-05-30|2003-07-09|Boots Co Plc|Use of a compound in the treatment of sleep disorders and the like,in providing refreshedness on waking and a method for the treatment of grogginess therewith|
    US20070059346A1|2003-07-01|2007-03-15|Todd Maibach|Film comprising therapeutic agents|
    US9561182B2|2003-08-22|2017-02-07|Cure Pharmaceutical Corporation|Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals|
    US20050079253A1|2003-10-10|2005-04-14|Hiroshi Nakamura|Bilayer edible sheet|
    AU2004289248B2|2003-11-07|2012-05-03|U.S. Smokeless Tobacco Company Llc|Tobacco compositions|
    US8627828B2|2003-11-07|2014-01-14|U.S. Smokeless Tobacco Company Llc|Tobacco compositions|
    US20040131662A1|2003-11-12|2004-07-08|Davidson Robert S.|Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films|
    US20050163858A1|2003-12-31|2005-07-28|Garth Boehm|Ziprasidone formulations|
    US20050186256A1|2004-02-20|2005-08-25|Dihel Deborah L.|Dissolvable film comprising an active ingredient and method of manufacture|
    US20050208108A1|2004-03-19|2005-09-22|Jannusch Leonard C|Thermoplastic films and methods for making|
    US8017667B2|2004-06-29|2011-09-13|Victoria University|Antimicrobial packaging material|
    JP4815798B2|2004-12-17|2011-11-16|大正製薬株式会社|Copper-containing composition for oral administration|
    US20070275135A1|2005-02-09|2007-11-29|First Flavor, Inc.|Taste sampling process and product|
    US20070087036A1|2005-05-03|2007-04-19|Durschlag Maurice E|Edible film for transmucosal delivery of nutritional supplements|
    US9101160B2|2005-11-23|2015-08-11|The Coca-Cola Company|Condiments with high-potency sweetener|
    US20070140992A1|2005-12-21|2007-06-21|Lynn Schick|Taste masking of essential oils using a hydrocolloid|
    EP2001448A2|2006-01-27|2008-12-17|Cadbury Adams USA LLC|Flavor-enhancing compositions, methods of manufacture, and methods of use|
    US7946296B2|2006-05-26|2011-05-24|Philip Morris Usa Inc.|Dissolvable tobacco film strips and method of making the same|
    US20070298078A1|2006-06-27|2007-12-27|Harrison Michael D|Water Soluble Article for Imparting Dietary Fiber to Bottled Water|
    US8017168B2|2006-11-02|2011-09-13|The Coca-Cola Company|High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith|
    US20080152761A1|2006-12-20|2008-06-26|Shiji Shen|Packaging of Food Products with Pullulan Films|
    DE102006061287A1|2006-12-22|2008-06-26|Lts Lohmann Therapie-Systeme Ag|Edible foil-shaped preparation with cola flavor|
    WO2008098195A2|2007-02-09|2008-08-14|Todd Maibach|Film comprising nitroglycerin|
    US20080220029A1|2007-03-05|2008-09-11|Charlene Ng|Fast-dissolving/disintegrating film preparation having high proportion of active|
    US20090011115A1|2007-03-13|2009-01-08|Foss Carter D|Edible Pullulan Films Containing Flavoring|
    EP2144601A4|2007-04-05|2012-10-10|Univ Kansas|Rapidly dissolving pharmaceutical compositions comprising pullulan|
    US8900629B2|2007-04-05|2014-12-02|University Of Kansas|Rapidly dissolving pharmaceutical compositions comprising pullulan|
    WO2008127902A2|2007-04-12|2008-10-23|Tate & Lyle Ingredients Americas, Inc.|Pullulan film containing sweetener|
    JP2009007311A|2007-06-29|2009-01-15|Lintec Corp|Diphenhydramine-acesulfame adduct, method for producing the same and oral preparation containing the adduct|
    JP2009096803A|2007-09-26|2009-05-07|Showa Kako Kk|Oral cavity patch type slowly soluble preparation|
    GB2453770A|2007-10-19|2009-04-22|Reckitt Benckiser Healthcare|Oral composition comprising a cooling agent|
    EP3093010A1|2007-10-19|2016-11-16|Reckitt Benckiser HealthcareLimited|Oral composition comprising a cooling agent|
    US20090196907A1|2008-01-31|2009-08-06|Bunick Frank J|Edible film-strips for immediate release of active ingredients|
    CA2711974A1|2008-01-31|2009-08-13|Mcneil-Ppc, Inc.|Edible film-strips with modified release active ingredients|
    DE102008029849A1|2008-06-25|2009-12-31|Henkel Ag & Co. Kgaa|Compositions for shaping keratinic fibers based on a natural, holding polymer combination|
    JP5646158B2|2008-11-07|2014-12-24|ツキオカフィルム製薬株式会社|Lactic acid bacteria-containing film and method for producing lactic acid bacteria-containing film|
    US20100256197A1|2009-04-02|2010-10-07|Silver Eagle Labs Nv, Llc|Nicotine Dissolving Film With Or Without Menthol|
    US20100256215A1|2009-04-02|2010-10-07|Silver Eagle Labs Nv, Llc|Menthol-Melatonin Dissolving Film|
    CN102470078A|2009-07-30|2012-05-23|宝洁公司|Oral care articles and methods|
    TR200907338A1|2009-09-28|2011-04-21|Yedi̇tepe Üni̇versi̇tesi̇|A film strip containing natural ingredients.|
    US20120003162A1|2010-06-30|2012-01-05|Mcneil-Ppc, Inc.|Methods of Preparing Non-Alcohol Bioactive Esential Oil Mouth Rinses|
    DE102010049708A1|2010-10-28|2012-05-03|Hexal Ag|Oral pharmaceutical film formulation for bitter-tasting drugs|
    KR101077468B1|2011-03-04|2011-11-07|차바이오앤디오스텍|Stable orodispersible film formulation|
    EP2732813A1|2012-11-14|2014-05-21|Hexal AG|Orodispersible film compositions|
    CA2905099A1|2013-03-14|2014-10-02|Altria Client Services Llc|Soft oral product|
    CN105813641A|2013-12-13|2016-07-27|帝斯曼知识产权资产管理有限公司|Novel use of biotin and natural essential oils for bovine animals for the prevention and treatment of ketosis|
    CA2935191C|2013-12-31|2021-11-09|Johnson & Johnson Consumer Inc.|Process for forming a shaped film product|
    MX2016008677A|2013-12-31|2017-05-11|Johnson & Johnson Consumer Inc|Process for forming a multi layered shaped film.|
    US9839939B2|2013-12-31|2017-12-12|Johnson & Johnson Consumer Inc.|Single-pass process for forming a multilayered shaped film product|
    CN104126656A|2014-07-22|2014-11-05|上海海洋大学|Chitosan-orange peel essential oil composite plastic wrap with bacteriostasis functions|
    WO2016103183A1|2014-12-23|2016-06-30|Celanese Sales Germany Gmbh|Taste modifying compositions|
    US20160183580A1|2014-12-23|2016-06-30|Celanese Sales Germany Gmbh|Taste modifying compositions|
    EP3713540A1|2017-11-21|2020-09-30|3M Innovative Properties Company|Oral plant-based-oil-in-water emulsions and methods of use|
    JP2021508325A|2017-12-20|2021-03-04|スリーエム イノベイティブ プロパティズ カンパニー|Oral composition and usage|
    AU2018392886B2|2017-12-20|2021-12-23|3M Innovative Properties Company|Oral compositions and methods of use|
    WO2021077369A1|2019-10-24|2021-04-29|The Procter & Gamble Company|Multilayer dissolvable solid article containing coating composition and process for making the same|
    WO2021077367A1|2019-10-24|2021-04-29|The Procter & Gamble Company|Multilayer dissolvable solid article containing coating composition and process for making the same|
    CN113440499A|2021-06-18|2021-09-28|北京斯利安药业有限公司|Folic acid oral dissolving film agent and preparation method thereof|
    法律状态:
    2009-01-08| PC1| Assignment before grant (sect. 113)|Owner name: MCNEIL-PPC, INC. Free format text: FORMER APPLICANT(S): WARNER-LAMBERT COMPANY LLC |
    2009-11-05| MK4| Application lapsed section 142(2)(d) - no continuation fee paid for the application|
    优先权:
    申请号 | 申请日 | 专利标题
    US10/423,398|US20030211136A1|1998-09-25|2003-04-25|Fast dissolving orally consumable films containing a sweetener|
    US10/423,398||2003-04-25||
    PCT/IB2004/001270|WO2004096192A1|2003-04-25|2004-04-13|Fast dissolving orally consumable films containing a sucralose as a sweetener|
    [返回顶部]